Glaukos (GKOS) | Stock Overview & Key Data
Glaukos Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $163.71 on January 20, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Glaukos GKOS | 5.85B Mid-cap | 2.41% | 9.54% | 18.97% | -31.66% | -30.85% | -15.00% | 111.96% | 172.66% |
| Abbott Laboratories ABT | 233.32B Mega-cap | -0.66% | -0.13% | 4.86% | 18.62% | 17.44% | 27.96% | 22.55% | 34.37% |
| Boston Scientific BSX | 154.34B Large-cap | -0.65% | 2.92% | 6.40% | 8.52% | 15.19% | 31.82% | 172.73% | 171.57% |
| Masimo MASI | 8.85B Mid-cap | -3.46% | -3.76% | 0.51% | -0.61% | -1.87% | 45.01% | 26.98% | -30.90% |
| Globus Medical GMED | 7.70B Mid-cap | -5.38% | -5.02% | -22.85% | -34.18% | -29.96% | -20.36% | 0.46% | 16.75% |
| Bio-Rad BIO.B | 7.10B Mid-cap | 0.00% | 0.00% | 3.34% | -26.66% | -23.19% | -11.77% | -49.77% | -49.64% |
Ownership & Short Interest
Glaukos Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Glaukos would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is GKOS's 52-week high and low?
In the last 52 weeks, Glaukos reached a high of $163.71 (on January 23, 2025) and a low of $77.10 (on May 1, 2025).
What is the market cap and P/E ratio for GKOS?
Curious about Glaukos's size and valuation? Its market capitalization stands at 5.85B. When it comes to valuation, the P/E ratio (trailing twelve months) is -37.81, and the forward P/E (looking ahead) is -93.12.
Does GKOS pay dividends? If so, what's the yield?
As for dividends, Glaukos isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Glaukos's main competitors or similar companies to consider before investing?
When looking at Glaukos, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Abbott Laboratories ABT | 233.32B | Healthcare | Medical Devices | 27.96% | 22.55% |
| Boston Scientific BSX | 154.34B | Healthcare | Medical Devices | 31.82% | 172.73% |
| Masimo MASI | 8.85B | Healthcare | Medical Devices | 45.01% | 26.98% |
| Globus Medical GMED | 7.70B | Healthcare | Medical Devices | -20.36% | 0.46% |
| Bio-Rad BIO.B | 7.10B | Healthcare | Medical Devices | -11.77% | -49.77% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Glaukos Corporation? (e.g., ROE, Debt/Equity)
To get a sense of Glaukos's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -20.36%, the Debt to Equity ratio from the most recent quarter is 14.09, and its Gross Profit Margin stands at 77.20%.
What is the recent revenue and earnings growth for GKOS?
Looking at Glaukos's growth, its revenue over the trailing twelve months (TTM) was $405M. Compared to the same quarter last year (YoY), quarterly revenue grew by 24.60%, and quarterly earnings saw a YoY growth of 24.58%.
How much of GKOS stock is held by insiders and institutions?
Wondering who owns Glaukos stock? Company insiders (like executives and directors) hold about 3.33% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.71%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.